Endosense is beginning to establish itself in the tough market of atrial fibrillation with a catheter that stresses an attribute that no one has featured yet: force sensing in delivering energy. Proving the clinical value of force-sensing will be difficult enough, but Endosense faced an even greater challenge in 2009 when its long-time backer, 3i, decided it wanted to exit device venture investing and divest its stake in the company.
by David Cassak
Eugene Kleiner, founder of the powerhouse venture capital firm, Kleiner Perkins, and one of the fathers of venture capital, once...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.
The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.
An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.
Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.
The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.
An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.
Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.
